Patient Experiences With CAR T-Cell and Bispecific Antibody Therapy

In this episode, we explore an exciting and rapidly evolving area of myeloma treatment: immunotherapy, with a focus on two groundbreaking approaches, CAR T-cell therapy and bispecific antibody therapy. These therapies are changing myeloma care, offering new hope for patients whose treatment no longer works. You’ll hear about the decisions they faced when considering these treatments; the ways they prepared mentally, physically, and emotionally; and what their experience has been.

Topics of discussion:      

(4:05) Decision-making process for CAR T-cell therapy

(8:15) Experience receiving CAR T-cell therapy

(12:35) Experience receiving bispecific antibody therapy

(14:58) Considerations for enrolling in a clinical trial

(20:15) Role of caregivers and patient advocates

(24:05 Managing side effects

(33:18) Impact of CAR T-cell and bispecific antibody therapy

This episode is supported by AbbVie, Amgen, CURE, Genentech, GSK, Johnson & Johnson, Karyopharm, Legend Biotech, Pfizer, Regeneron, and Sanofi.

To learn more about CAR T-cell therapy, download A Guide to CAR T-Cell Therapy in Myeloma here.

To learn more about bispecific antibody therapy, download Bispecific Antibodies for Multiple Myeloma: What you Need to Know here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.